Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: Protocol for a systematic review

被引:10
|
作者
Bem D. [1 ]
Dretzke J. [1 ,2 ]
Stevens S. [1 ]
Lordkipanidzé M. [3 ,4 ]
Hodgkinson J. [5 ]
Bayliss S. [1 ]
Moore D. [1 ]
Fitzmaurice D. [5 ]
机构
[1] Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham
[2] NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham
[3] Montreal Heart Institute, Research Centre, 5000 rue Bélanger, Montréal, H1T 1C8, QC
[4] Faculté de pharmacie, Université de Montreal, C.P. 6128, Succ. Centre-ville, Montreal, H3C 3J7, QC
[5] Primary Care Clinical Sciences, School of Health and Population Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham
关键词
Aspirin; Aspirin doses; Aspirin regimens; Cardiovascular disease; Primary prevention; Secondary prevention; Split dosing; Systematic review; Timing;
D O I
10.1186/s13643-015-0078-3
中图分类号
学科分类号
摘要
Background: Once-daily low-dose aspirin is routinely used for the prevention of secondary events in cardiovascular disease (CVD). The routine use of aspirin in primary prevention of CVD is less clear due to a finer balance between benefits and harms. In addition, the variability in benefit achievable from the prescription of aspirin has led to a growing interest in considering whether there are more effective aspirin regimens than once-daily dosing or whether effectiveness is influenced by the time of day aspirin is taken (chronotherapy). The proposed systematic review will evaluate the evidence on the effects of different aspirin regimens used in terms of number of doses (e.g. split or alternate dosing) or dosing time of aspirin (e.g. morning versus evening) in primary and secondary prevention of CVD. Methods/design: Standard systematic review methodology will be employed for study identification, selection and data extraction. Electronic databases will be searched incorporating terms relating to population and the intervention. No date or language limitations will apply. Systematic reviews and controlled studies comparing different aspirin regimens-in terms of frequency or timing-for primary and/or secondary prevention of CVD will be included. No restrictions on outcome will apply. Quality assessment will be appropriate for each study design. The data will be tabulated and narratively synthesised. Meta-analysis may be undertaken where clinical and methodological homogeneity exists. Discussion: There are a number of published and ongoing primary studies that investigate the cardiovascular protective effect of different aspirin regimens. However, no systematic review to date has attempted to review the evidence pertaining to aspirin dosing regimens differing in frequency and/or in timing. The proposed systematic review will cover both the above questions and could potentially be beneficial for reconsidering the current practice of managing patients with aspirin in primary care. Systematic review registration: PROSPERO CRD42014010596 © Bem et al. 2015.
引用
收藏
相关论文
共 50 条
  • [1] The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
    Bem, D.
    Lordkipanidze, M.
    Hodgkinson, J.
    Stevens, S.
    Bayliss, S.
    Moore, D.
    Fitzmaurice, D.
    Dretzke, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) : 500 - 512
  • [2] Aspirin for Primary and Secondary Prevention of Cardiovascular Disease
    Godley, Robert W.
    Hernandez-Vila, Eduardo
    TEXAS HEART INSTITUTE JOURNAL, 2016, 43 (04): : 318 - 319
  • [3] Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events
    Kim, Joonseok
    Becker, Richard C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (03) : 493 - 504
  • [4] Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events
    Joonseok Kim
    Richard C. Becker
    Journal of Thrombosis and Thrombolysis, 2016, 41 : 493 - 504
  • [5] Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
    Marquis-Gravel, Guillaume
    Stebbins, Amanda
    Wruck, Lisa M.
    Roe, Matthew T.
    Effron, Mark B.
    Hammill, Bradley G.
    Whittle, Jeff
    VanWormer, Jeffrey J.
    Robertson, Holly R.
    Alikhaani, Jacqueline D.
    Kripalani, Sunil
    Farrehi, Peter M.
    Girotra, Saket
    Benziger, Catherine P.
    Polonsky, Tamar S.
    Merritt, J. Greg
    Gupta, Kamal
    McCormick, Thomas E., III
    Knowlton, Kirk U.
    Jain, Sandeep K.
    Kochar, Ajar
    Rothman, Russell L.
    Harrington, Robert A.
    Hernandez, Adrian F.
    Jones, W. Schuyler
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (04):
  • [6] Aspirin for the Prevention of Cardiovascular Disease Systematic Review
    Leaberry, Brooke Adams
    JOURNAL OF NURSING CARE QUALITY, 2010, 25 (01) : 17 - 21
  • [7] Aspirin in secondary prevention of cardiovascular diseases: systematic review
    Campbell, C. L.
    Smyth, S.
    Montalescot, G.
    Steinhubl, S. R.
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2009, 20 (86): : 61 - 62
  • [8] Primary and secondary prevention of cardiovascular disease in diabetes with aspirin
    Schnell, Oliver
    Erbach, Michael
    Hummel, Michael
    DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (04): : 245 - 255
  • [9] Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
    Jones, W. S.
    Mulder, H.
    Wruck, L. M.
    Pencina, M. J.
    Kripalani, S.
    Munoz, D.
    Crenshaw, D. L.
    Effron, M. B.
    Re, R. N.
    Gupta, K.
    Anderson, R. D.
    Pepine, C. J.
    Handberg, E. M.
    Manning, B. R.
    Jain, S. K.
    Girotra, S.
    Riley, D.
    DeWalt, D. A.
    Whittle, J.
    Goldberg, Y. H.
    Roger, V. L.
    Hess, R.
    Benziger, C. P.
    Farrehi, P.
    Zhou, L.
    Ford, D. E.
    Haynes, K.
    VanWormer, J. J.
    Knowlton, K. U.
    Kraschnewski, J. L.
    Polonsky, T. S.
    Fintel, D. J.
    Ahmad, F. S.
    McClay, J. C.
    Campbell, J. R.
    Bell, D. S.
    Fonarow, G. C.
    Bradley, S. M.
    Paranjape, A.
    Roe, M. T.
    Robertson, H. R.
    Curtis, L. H.
    Sharlow, A. G.
    Berdan, L. G.
    Hammill, B. G.
    Harris, D. F.
    Qualls, L. G.
    Marquis-Gravel, G.
    Modrow, M. F.
    Marcus, G. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, : 1981 - 1990
  • [10] Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
    Jones, W. Schuyler
    Mulder, Hillary
    Wruck, Lisa M.
    Pencina, Michael J.
    Kripalani, Sunil
    Munoz, Daniel
    Crenshaw, David L.
    Effron, Mark B.
    Re, Richard N.
    Gupta, Kamal
    Anderson, R. David
    Pepine, Carl J.
    Handberg, Eileen M.
    Manning, Brittney R.
    Jain, Sandeep K.
    Girotra, Saket
    Riley, Danielle
    DeWalt, Darren A.
    Whittle, Jeff
    Goldberg, Ythan H.
    Roger, Veronique L.
    Hess, Rachel
    Benziger, Catherine P.
    Farrehi, Peter
    Zhou, Li
    Ford, Daniel E.
    Haynes, Kevin
    VanWormer, Jeffrey J.
    Knowlton, Kirk U.
    Kraschnewski, Jennifer L.
    Polonsky, Tamar S.
    Fintel, Dan J.
    Ahmad, Faraz S.
    McClay, James C.
    Campbell, James R.
    Bell, Douglas S.
    Fonarow, Gregg C.
    Bradley, Steven M.
    Paranjape, Anuradha
    Roe, Matthew T.
    Robertson, Holly R.
    Curtis, Lesley H.
    Sharlow, Amber G.
    Berdan, Lisa G.
    Hammill, Bradley G.
    Harris, Debra F.
    Qualls, Laura G.
    Marquis-Gravel, Guillaume
    Modrow, Madelaine F.
    Marcus, Gregory M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (21): : 1981 - 1990